97 results about "Fusobacterium nucleatum" patented technology

The invention discloses tyrosine phenol-lyase (TPL) mutant of fusobacterium nucleatum, a gene, a carrier, an engineered bacteria strain, and applications of the TPL mutant of fusobacterium nucleatum in synthetizing levodopa. Compared with the wild type, the TPL mutant of fusobacterium nucleatum provided by the invention has the more excellent catalytic performance. The accumulated concentration in synthesizing levodopa of the TPL mutant of fusobacterium nucleatum achieves 140g/L or above, compared with that of the wild type, the accumulated concentration is improved by 17-25 %, and the optical purity is greater than 99.5%; the conversion rate of the substrate, namely, catechol achieves 99.8% or above, and compared with that of the wild type, the conversion rate is improved by 15-20 %.

Methods and materials for detecting colorectal cancer using DNA markers from human stool. More specifically, methods and materials for quantification of FNN bacteria DNA per unit stool weight as a molecular marker for CRC diagnosis.

The invention relates to a method for calculating a flora balanced relation index in an individual excrement sample, and an application of the method in screening, diagnosis or auxiliary diagnosis incolorectal cancer (CRC). By extracting bacteria in excrement during DNA sequencing, the types and quantity characteristics of the bacteria can be obtained, and a CRC diagnosis by taking quantity ratiocharacteristic of a plurality of bacteria as a base is carried out. Compared with the methods used in clinical diagnosis or noninvasive screening of CRC with an applied patent, the method is completely noninvasive, and can realize accurate diagnosis of CRC. The analysis result displays that a ratio of fusobacterium nucleatum Fn to bifidobacteria Bb quantity (Fn/Bb) has high susceptibility and specificity on CRC screening, which can respectively reach 84.6% and 92.3% (AUC=0.911). the ratio of fusobacterium nucleatum Fn to clostridium leptum Fp (Fn/Fp) quantity is combined to increase the diagnosis value on CRC, and the Area Under Curve (AUC) of a subject work characteristic curve can reach 0.943. In addition, combination of Fn/Bb and Fn/Fp quantity ratio for screening I-stage CRC has 60% of specificity and 90% of sensitivity.

The invention discloses a nucleic acid combination for detecting Fusobacterium nucleatum in night soil, and applications and kits thereof, and belongs to the technical field of biomedical examination. The nucleic acid combination for detecting Fusobacterium nucleatum in night soil can specifically detect the Fusobacterium nucleatum. The nucleic acid combination is used to prepare a kit for detecting Fusobacterium nucleatum in night soil and a kit for detecting cancer. The kits effectively improve the detection precision, can be conveniently and fast applied to detect the Fusobacterium nucleatum, and have high sensitivity and specificity. A technologic method provided by the invention can be used to conveniently extract Fusobacterium nucleatum genome from the night soil, and has the advantages of quantitative detection of the Fusobacterium nucleatum, simplicity in operation, and facilitation of promotion and application.

The invention discloses supramolecular hydrogel and also discloses a preparation method and application of the supramolecular hydrogel. The supramolecular hydrogel disclosed by the invention is prepared from a 2-deoxy-2-fluoro-guanosine analogue and silver ions. The silver-ion supramolecular antibacterial hydrogel provided by the invention has the advantages of simplicity in preparation, low toxicity, good biocompatibility, excellent stable performance and the like; the silver ions can be effectively alleviated and the antibacterial activity is good; especially, the silver-ion supramolecular antibacterial hydrogel has relatively high antibacterial activity on methicillin-resistant staphylococcus aureus ATCC25923 and ATCC33591, and fusobacterium nucleatum; the silver-ion supramolecular antibacterial hydrogel is prepared into an antibacterial material and has a relatively good application prospect.

The invention discloses IgY mouthwash prepared by anti-porphyromonas gingivalis and an IgY antibody with fusobacterium nucleatum specificity, which is used for preventing gingivitis and gingivitis ozostomia. The IgY mouthwash comprises an IgY preparation for resisting periodontal pathogens and basic mouthwash materials, wherein the IgY preparation for resisting periodontal pathogens is prepared by raw materials according to the following mass percent accounting for the total mass of toothpaste: 0.01%-0.5% of anti-porphyromonas gingivalis and IgY antibody preparation with fusobacterium nucleatum specificity, 0.01-2.0% of chlorhexidine, 1.0-30.0% of glycerol, and 0.1-2.0% of polyvinylpyrrolidone, wherein a protective preparation of the anti-porphyromonas gingivalis and the IgY antibody preparation with fusobacterium nucleatum specificity is prepared by the chlorhexidine, the glycerol, and the polyvinylpyrrolidone. The IgY mouthwash which is disclosed by the invention and is used for treating and preventing gingivitis and ozostomia has an obvious effect on treating and preventing the gingivitis and the ozostomia.

The application provides a lactobacillus paracasei PC-01 isolated from sour yak milk in Longren Township, Dangxiong County, Lhasa, Tibet, wherein the microbial preservation number of the lactobacillus paracasei PC-01 is CGMCC No.17537. The Lactobacillus paracasei PC-01 can improve oral health flora imbalance, has probiotics with better acid tolerance and bile salt tolerance, has probiotic characteristics, can be directly taken as a preparation for improving oral microecological environment, or as a raw material to prepare a microbial antagonist for pathological states in oral cavity, wherein the pathological state microorganisms comprise at least one of streptococcus mutans, Porphyromonas gingivalis, Treponema denticola, Genus Prevotella and Fusobacterium nucleatum.

The invention discloses an anti-porphyromonas gingivalis and fusobacterium nucleatum compound specific IgY preparation. According to the preparation, 10-70 parts by weight of porphyromonas gingivalis thalli and thalli fragments, and 30-90 parts by weight of fusobacterium nucleatum thalli and thalli fragments are compounded into an antigen to immune an egg laying hen. The invention also discloses the specific preparation method of the anti-porphyromonas gingivalis and fusobacterium nucleatum compound specific IgY preparation, and toothpaste containing the anti-porphyromonas gingivalis and fusobacterium nucleatum compound specific IgY preparation. By the IgY toothpaste which is used for treating and preventing gingivitis and ozostomia has obvious effects in preventing and treating the gingivitis and the ozostomia.

The invention provides a Fusobacterium nucleatum subsp. animalis strain THCT6b3 separated from human intestines. A 16SrRNA gene sequence of the strain is shown in SEQ ID NO:1. The classification nameof the strain is Fusobacterium nucleatum subsp. animalis and collected on May 17, 2019 with the collection number of CCTCC NO:M 2019363 in the China Center for Type Culture Collection. The invention further provides application of the strain in detection of Fusobacterium nucleatum. A PCR-based molecular identification method for Fusobacterium nucleatum subsp. animalis is established for the firsttime. The strain can promote disclosing of composition and sources of the Fusobacterium nucleatum in intestines of colorectal cancer patients, and contributes to analysis of molecular epidemiologic characteristics of the Fusobacterium nucleatum.

The invention discloses a colorectal cancer auxiliary diagnosis kit for fecal nucleic acid detection and a use method of the colorectal cancer auxiliary diagnosis kit. The kit comprises a KRAS gene mutation detection reagent, a fusobacterium nucleatum detection reagent, a DNA sulfite conversion reagent and a Septin9, SDC2, HOXA11 and NDRG4 gene methylation detection reagent. The use method comprises the following steps: collecting an excrement sample, and then completing DNA purification, KRAS gene mutation detection, fusobacterium nucleatum abundance detection and Septin9, SDC2, HOXA11 and NDRG4 gene methylation detection of the sample by using reagents in the kit; and calculating the obtained data through a logistic regression model, and performing result evaluation and analysis. The colorectal cancer detection sensitivity reaches 89% or above, the specificity reaches 94% or so, high-sensitivity and high-specificity colorectal cancer detection can be achieved, and doctors can be helped to guide follow-up treatment medication of patients.

The invention relates to the technical field of microorganisms, and discloses lactobacillus plantarum for preventing and/or treating periodontitis as well as a culture, preparation and application of the lactobacillus plantarum. The name of the lactobacillus plantarum is Lactobacillus plantarum CCFM1137, the lactobacillus plantarum is preserved in Guangdong Microbial Culture Collection Center on the 5th floor of the Building 59, No. 100 Courtyard, Xianlie Middle Road, Guangzhou on August 1, 2020, and the preservation number is GDMCC No: 61114. The lactobacillus plantarum can be used for inhibiting the formation of a mixed bacterium biological membrane of porphyromonas gingivalis, prevotella intermedia and fusobacterium nucleatum; the content of inflammatory factors in a periodontitis cell model can be reduced; the expression quantity of transmembrane transport protein in a periodontitis cell model can be increased; and the lactobacillus plantarumcan be used for preventing and/or treating oral diseases and inhibiting prevotella intermedia, porphyromonas gingivalis and/or fusobacterium nucleatum.

The invention provides a fusobacterium nucleatum subsp.animalis strain THCT5A4 separated from human rectal cancer tumor tissue. A classification name is Fusobacterium nucleatum subsp.animalis THCT5A4,a preservation number of the fusobacterium nucleatum subsp.animalis strain THCT5A4 separated from the human rectal cancer tumor tissue is CCTCC NO: M 2019366, the preservation date is May 17th, 2019,the preservation organization is China General Microbiological Culture Collection Center, and a 16SrRNA gene sequence of the fusobacterium nucleatum subsp.animalis strain THCT5A4 separated from the human rectal cancer tumor tissue is shown in SEQ ID NO:1 as shown in the description. A separation method of the fusobacterium nucleatum subsp.animalis strain is provided. A result of co-culture of a colorectal cancer cell line and the THCT5A4 shows that the THCT5A4 can significantly promote proliferation of colorectal cancer cells, therefore, the THCT5A4 can provide diverse in-vitro or in-vivo experimental conditions for simulating an intestinal environment for studies of colorectal cancer, and a colorectal cancer disease model can be built for screening medicines for treating colorectal cancer.

The invention provides a fusobacterium nucleatum polymorphic subspecies isolate THCT15E1, a classification name is Fusobacterium nuucleates subsp.nucleatum THCT15E1, a preservation number of the strain is CCTCC NO: M 2019362, a preservation date is May 17, 2019, a preservation unit is China Center for Type Culture Collection, and the 16SrRNA gene sequence of the strain is shown as SEQ ID NO: 1. The result of co-culture of the colorectal cancer cell line and THCT15E1 shows that THCT15E1 can significantly promote colorectal cancer cell proliferation; therefore, the THCT15E1 can provide diversified experimental conditions for in-vitro or in-vivo intestinal environment simulation for colorectal cancer research, and can also construct a colorectal cancer disease model to screen drugs for treating colorectal cancer.

The invention provides a primer compound for identifying intestinal microecological state and an application thereof. The primer compound is a specific primer designed for intestinal bacterium 16S rRNA; the specific primer includes random basic groups; the quantity of random basic groups is 3-5; the intestinal bacterium includes any one of or combination of at least two of symbiotic clostridia, bifidobacterium adolescentis, fusobacterium nucleatum, peptostreptococcus anaerobius or klebsiella. A kit researched and developed on the basis of the primer compound provided by the invention has a specificity for detecting intestinal microecological imbalance reaching up to 92.5% and a sensitivity reaching up to 80.43%.

The invention relates to a preparation containing Fusobacterium nucleatum and PD-L1 antibody and used for immunotherapy of colorectal cancer, application of the preparation, a Fusobacterium nucleatummarker to predict curative effect of PD-L1 antibody therapy of colorectal cancer, and application of the marker. The influence of Fusobacterium nucleatum upon PD-L1 antibody immunotherapy of colorectal cancer is studied deeply herein, and it is discovered that PD-L1 monoclonal antibody therapy is more effective to colorectal cancer in the presence of Fusobacterium nucleatum, while PD-L1 monoclonalantibody therapy helps evidently extend the lifetime of a mouse with colorectal cancer in the presence of Fusobacterium nucleatum; by discussing the mechanism of Fusobacterium nucleatum, it is discovered that Fusobacterium nucleatum can provide transcriptional control for the expression of PD-L1; after PD-L1 antibody therapy is carried out for colorectal cancer tissues in the presence of Fusobacterium nucleatum, the proportion of CD8 positive T cells is increased; all these above are good for the effect of PD-L1 antibody therapy. It is indicated that the presence or absence of Fusobacterium nucleatum is suitable for acting as a potential marker to judge the curative effect of PD-L1 monoclonal antibody therapy for the patient with colorectal cancer; Fusobacterium nucleatum and PD-L1 monoclonal antibody can form an immunotherapy preparation for patients with colorectal cancer.

The invention particularly discloses Lactiplantibacillus plantarum HNU082 with an antagonistic effect and application thereof. The strain is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on March 9, 2021, the preservation number is GDMCC NO 61552: and the preservation address is the 5 floor, Laboratory Building of the Institute of Microbiology, #100, Middle Xianlie Road, Guangzhou City, China; and the taxonomic name is Lactiplantibacillus plantarum. According to the Lactiplantibacillus plantarum HNU082 disclosed by the invention, one strain of Lactiplantibacillus plantarum HNU082 is screened from a lot of samples; the strain has a relatively good antagonistic effect on Fusobacterium nucleatum in vitro or in vivo; furthermore, the Lactiplantibacillus plantarum HNU082 can be used for inducing the generation of anti-inflammatory cytokines and enhancing intestinal and systemic immune responses; the growth of pathogenic bacteria is inhibited through reducing the pH (potential of Hydrogen) value and the content of short-chain fatty acid is increased, so that the expression of inflammatory factors is reduced; and a feasible intervention strategy is provided for in-vivo antagonism of probiotics on the Fusobacterium nucleatum and a reliable basis is provided for preventing early-stage colorectal cancer.

The present invention relates to agents and compositions for the modification of the growth of bacterial cells. Thus, the compounds of the present invention are useful for the prevention and/or treatment of a disease in a subject. In particular, the present invention relates to the field of repurposing pharmaceutical compounds for treatment strategies of infectious diseases, gastrointestinal disorders, inflammatory diseases, proliferative diseases, metabolic disorders, cardiovascular diseases, and immunological diseases. Some of the compounds of the present invention demonstrate high specificity in inhibiting the growth of single bacterial species. Such compounds enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development strategies in order to reduce side effects of antibacterial treatment plans. Particularly interesting compounds of this invention are effective against pathobiological species such as Clostridium difficile, Clostridium perfingens, Fusobacterium nucleatum, and an enterotoxigenic strain of Bacteroides fragilis. Other compounds of the present invention reveal a strong inhibitory effect on a broad spectrum of bacterial species. Such compounds are useful for broad-spectrum antibiotic therapies of infections with unknown causative infecting bacterial species. Both types of compounds, especially the ones with narrow-spectrum antibacterialactivity, can further be used for modulating the microbiome composition and targeting species associated with dysbiosis and disease.

The invention discloses a kit for detecting colorectal cancer indicator bacteria. The kit is characterized by comprising the following components: a specific primer combination for identifying the indicator bacteria, wherein the primer combination is shown as SEQ ID NO. 1-14, and the indicator bacteria are the combination of fusobacterium nucleatum (F.nucleolus), anaerobic digestion streptococcus(P.anaerobicus), clostridium symbiosum (C.symbiolum), Porphyromonas saccharolytica (P.asaccharolytica), Prevotella intermedia (P.intermedia), Bacteroides fragilis (B.fragilis) and Streptococcus salivarius (S.salivarius). The kit for detecting colorectal cancer indicator bacteria disclosed by the invention has the beneficial effects that the colorectal cancer can be identified only by collecting astool sample. The principle is that the aim of identifying the colorectal cancer by detecting the colorectal cancer pathogenic bacteria in excrement, the sensitivity can reach 92.9%, and the specificity is 92.6%.